Chronic low-grade inflammation in aging — inflammaging — is mechanistically orchestrated through five convergent signaling hubs: NF-κB, NLRP3 inflammasome, cGAS-STING, JAK/STAT, and p38 MAPK. These nodes receive upstream input from at least four distinct drivers — immunosenescence, gut microbiome dysbiosis, metabolic dysfunction, and cellular senescence — suggesting that standard circulating biomarkers like IL-6, TNF-α, and CRP capture only surface-level readouts of a far deeper causal architecture.
The paradigm shift here is conceptually significant. Framing inflammaging as a set of druggable mechanisms rather than a biomarker cluster opens genuinely new therapeutic territory. Senotherapeutics (senolytics and senomorphics), NLRP3 inhibitors like MCC950, JAK inhibitors already approved for autoimmune conditions, and cGAS-STING modulators now in oncology trials each represent distinct pharmacological entry points into the same inflammatory biology that accelerates cardiovascular disease, neurodegeneration, and metabolic decline. This convergence matters practically: it means interventions targeting one hub may produce systemic anti-aging effects beyond their primary indication.
Critically, this is a narrative review — no original data, no cohort, no effect sizes. Its value lies in conceptual synthesis, not causal proof. The 'druggable inflammaging' framing, while compelling, still awaits rigorous human RCT validation for most proposed agents. For health-conscious adults, the actionable near-term implication remains gut health optimization and metabolic fitness, which modulate several upstream drivers simultaneously. Incremental as science, but editorially useful as a framework for clinicians and researchers navigating an increasingly fragmented field.